Stock EPI ESSA PHARMA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company ESSA Pharma Inc Toronto S.E.

Equities

EPI

CA29668H1047

Biotechnology & Medical Research

Business Summary

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Managers

Managers TitleAgeSince
David Parkinson CEO
 Chief Executive Officer 73 15-06-23
David Wood DFI
 Director of Finance/CFO 66 13-09-30
Peter Virsik COO
 Chief Operating Officer - 16-07-31
Alessandra Cesano CTO
 Chief Tech/Sci/R&D Officer 63 19-07-14

Members of the board

Members of the board TitleAgeSince
Franklin Berger BRD
 Director/Board Member 74 15-03-04
Sanford Zweifach BRD
 Director/Board Member 68 19-07-30
Richard Glickman CHM
 Chairman 65 10-09-30
Alex Martin Martin BRD
 Director/Board Member 55 19-07-30
Scott Requadt BRD
 Director/Board Member 56 16-01-13
David Parkinson CEO
 Chief Executive Officer 73 15-06-23
Philip Kantoff BRD
 Director/Board Member 69 22-09-12
Ann Thorell BRD
 Director/Board Member 56 19-07-30
Gary Sollis BRD
 Director/Board Member 69 12-04-25
Lauren Merendino BRD
 Director/Board Member 49 23-06-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 44,238,147 43,230,299 ( 97.72 %) 0 97.72 %

Shareholders

NameEquities%Valuation
BVF, Inc.
19.78 %
8,748,629 19.78 % 74 M $
Bellevue Asset Management AG
17.85 %
7,898,583 17.85 % 67 M $
Soleus Capital Management LP
9.783 %
4,327,622 9.783 % 37 M $
Morgan Stanley Capital Services LLC
9.464 %
4,186,578 9.464 % 36 M $
PFM Health Sciences LP
7.375 %
3,262,500 7.375 % 28 M $
RTW Investments LP
5.196 %
2,298,662 5.196 % 20 M $
Adage Capital Partners GP LLC
2.568 %
1,135,931 2.568 % 10 M $
Janus Henderson Investors US LLC
2.463 %
1,089,482 2.463 % 9 M $
Franklin Berger
1.773 %
784,404 1.773 % 7 M $
Rock Springs Capital Management LP
1.530 %
677,005 1.530 % 6 M $

Company contact information

ESSA Pharma, Inc.

999 West Broadway Suite 720

V5Z 1K5, Vancouver

+

http://www.essapharma.com
address ESSA Pharma Inc(EPI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPIX Stock
  4. EPI Stock
  5. Company ESSA Pharma Inc